Travere Therapeutics (TVTX) Return on Invested Capital (2014 - 2026)

Travere Therapeutics (TVTX) has 13 years of Return on Invested Capital data on file, last reported at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Invested Capital rose 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (up 1.0% YoY), and the FY2025 full-year result was 0.01%, up 1.0% from the prior year.
• Return on Invested Capital for Q1 2026 stood at 0.01%, up from 0.01% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.01% in Q1 2026 and bottomed at 0.13% in Q3 2024.
• The 5-year median for Return on Invested Capital is 0.02% (2025), against an average of 0.03%.
• The widest annual swing landed in 2024, when Return on Invested Capital slipped 12 bps; it then grew 12 bps in 2025.
• A 5-year view of Return on Invested Capital shows it stood at 0.04% in 2022, then surged by 60 bps to 0.02% in 2023, then sank by 142 bps to 0.04% in 2024, then jumped by 83 bps to 0.01% in 2025, then advanced by 20 bps to 0.01% in 2026.
• The last three Return on Invested Capital figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.

Peer Comparison